Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit...
Clinical Trial
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare...
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ...
180 Life Sciences Announces Presentation at the Gordon Conference
PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
BioAtla Announces Change in Executive Leadership
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the CongressDUBLIN, Ireland and BRIDGEWATER, N.J., Feb....
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher diseaseBETHESDA, Md., Feb. 27, 2023 (GLOBE...
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancerFLORHAM PARK, N.J., Feb....
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Double Masked, Placebo Control Study at Three Prominent U.S. SitesLOS ANGELES, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Levation Pharma Ltd.,...
Apexigen Announces Review of Strategic Alternatives and Restructuring
SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative...
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative...
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer Lyra Therapeutics CTO John Bishop, Ph.D. WATERTOWN, Mass.,...
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ,...
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving...